Leqembi, the first drug proven to slow the progression of Alzheimer’s disease, was granted full approval from US Food and Drug Administration on Thursday. With this, Medicare and other insurance plans can now cover Alzheimer’s treatment. Leqembi is priced at about $26,500 for a year. It was found to clear amyloid plaque buildup in brain associated with the memory-robbing disease.
Public Portal Access Please Login/Register